Hypercalcemia in Individuals with MGUS: Results from the iStopMM Study

Multiple Myeloma in 2023: An Oncological Success Story | Peter Forsberg, MDПодробнее

MGUS and Risk of Chronic Kidney Disease: Results of the Population-Based iStopMM StudyПодробнее

Screening for Monoclonal Gammopathy of Undetermined Significance: First Results from iStopMM StudyПодробнее

Updates from the iStopMM studyПодробнее

iStopMM analysis results: autoimmune diseases are not associated with MGUSПодробнее

Prevalence of Smoldering Multiple Myeloma: Results from the iStopMM StudyПодробнее

iSTOPMM study and early MGUS and SMM screening | Joshua Richter, MD | ASH 2021Подробнее

MGUS with Multiple Paraproteins: Results from the Population-Based iStopMM Screening StudyПодробнее

Autoimmune Diseases Are Not Associated with MGUS: Results of the Population-Based iStopMMПодробнее

iStopMM: a new, large & unbiased MGUS patient populationПодробнее

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myelomaПодробнее

Estimating Selection Bias in Previous MGUS Research-the Importance of Screening Results from iStopMMПодробнее

Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm StudyПодробнее

Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from iStopMMПодробнее

Circulating Tumor Plasma Cells in the Screened iStopMM Smoldering Multiple Myeloma CohortПодробнее

Benefits of Early MGUS Screening: Istopmm Study Results | Sæmundur Rögnvaldsson, MD, PhD | ASH 2023Подробнее

MGUS and Thrombotic Events: Istopmm Study Results | Sæmundur Rögnvaldsson, MD, PhD | ASH 2023Подробнее

iStopMM - One Year UpdateПодробнее

An insight into the prevalence of various subtypes of MGUS in the iStopMM studyПодробнее